Pfizer asks FDA to authorize its booster for 16-17 year olds
Pfizer yesterday asked the Food and Drug Administration to expand the emergency use authorization for its COVID-19 vaccine booster to include youth aged 16 and 17.
“It is our hope to provide strong protection for as many people as possible, particularly in light of the new variant,” tweeted Pfizer CEO Albert Bourla.
FDA last month authorized, and the Centers for Disease Control and Prevention recommends (https://www.cdc.gov/media/releases/2021/s1119-booster-shots.html), a single booster dose of the Pfizer or Moderna COVID-19 vaccine for all individuals aged 18 or older at least six months after receiving the initial two-dose series or two months after receiving the single-dose Johnson & Johnson vaccine.
Related News Articles
Headline
The Department of Health of Human Services Aug. 21 issued a request for information seeking feedback on immunization categories within the Aug. 10 executive…
Headline
For the 2025-2026 school year, exemptions from one or more vaccines among U.S. kindergartners was at 4.2%, increasing from 3.6% for the previous school year,…
Headline
The Department of Health and Human Services June 30 announced it will terminate emergency use authorization declarations for certain drugs and medical devices…
Headline
The Centers for Disease Control and Prevention Feb. 19 released a report on the low use of COVID-19 antiviral drugs among individuals age 65 and older, a…
Headline
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…
Headline
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…